Related Experiment Videos
Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with
Abstract:
Macrophage-activating factor (MAF) was obtained from cultures of normal F344 rat lymphocytes incubated with insoluble concanavalin A. The MAF rendered macrophages from normal C57BL/6 mice cytotoxic against the syngeneic B16 melanoma and the allogeneic AC 15091. At the same time, normal syngeneic or allogeneic embryo cells were unharmed, even in the presence of susceptible tumor cells. Optimal MAF levels followed incubation of lymphocytes for 48 hr with Sepharose-bound concanavalin A. A 2-hr incubation of macrophages with MAF was sufficient to initiate activation, providing that 46 hr were allowed to elapse before tumor cells were added. The MAF activity was enhanced after heating the supernatant to 199 degrees. Control experiments largely excluded the possibility that residual unbound concanavalin A caused the observed macrophage-mediated tumoricidal effects.
Insights
This study shows that macrophage-activating factor (MAF) derived from rat lymphocytes can selectively kill tumor cells, including B16 melanoma, without harming normal embryo cells. MAF activation of macrophages is a promising avenue for cancer therapy.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Macrophages are key immune cells involved in tumor surveillance.
- Tumor cells often evade immune responses.
- Identifying factors that activate macrophages against tumors is crucial for cancer therapy.
Purpose of the Study:
- To investigate the ability of macrophage-activating factor (MAF) to induce cytotoxic activity in macrophages.
- To determine the specificity of MAF-induced macrophage cytotoxicity against tumor cells versus normal cells.
- To optimize the production and activation conditions for MAF.
Main Methods:
- Normal F344 rat lymphocytes were cultured with insoluble concanavalin A to obtain MAF.
- MAF was used to treat macrophages from normal C57BL/6 mice.
- Macrophage cytotoxicity was assessed against syngeneic B16 melanoma and allogeneic AC 15091 tumor cells, as well as normal syngeneic and allogeneic embryo cells.
- Optimization of MAF production involved varying lymphocyte incubation times and using Sepharose-bound concanavalin A.
- Macrophage activation kinetics and the effect of heat treatment on MAF activity were evaluated.
Main Results:
- MAF induced significant cytotoxicity in macrophages against both syngeneic and allogeneic tumor cells.
- Normal syngeneic and allogeneic embryo cells remained unharmed, demonstrating selective tumoricidal activity.
- Optimal MAF production was achieved after 48 hours of lymphocyte incubation with Sepharose-bound concanavalin A.
- A 2-hour incubation of macrophages with MAF was sufficient for activation, followed by a 46-hour delay before tumor cell addition.
- MAF activity was enhanced by heating the supernatant to 199 degrees.
- Control experiments ruled out residual concanavalin A as the cause of tumoricidal effects.
Conclusions:
- Macrophage-activating factor (MAF) effectively activates macrophages to selectively kill tumor cells.
- MAF demonstrates potential as a therapeutic agent for cancer treatment due to its tumor-specific cytotoxicity.
- Further research into MAF production and activation protocols could lead to novel immunotherapies.